EMA Says CHMP Has Recommended Granting A Marketing Authorisation In European Union For Rasonque (Daraxonrasib) For Metastatic Pancreatic Cancer

The European Medicines Agency (EMA) has announced that its Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Rasonque (Daraxonrasib) in the European Union, aimed at treating metastatic pancreatic cancer. This recommendation is a significant step for the product's availability in the EU market, potentially impacting the stock performance of the company, RVMD.